Overview

Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome

Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This treatment plan is intended for the use of UX007 (triheptanoin) in the treatment of a single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome.
Details
Lead Sponsor:
Amy Goldstein
Jerry Vockley, MD, PhD
Collaborator:
Ultragenyx Pharmaceutical Inc